PMID- 37667507 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231108 IS - 1555-3892 (Electronic) IS - 0963-6897 (Print) IS - 0963-6897 (Linking) VI - 32 DP - 2023 Jan-Dec TI - HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic gammadelta T-cell Lymphoma. PG - 9636897231194265 LID - 10.1177/09636897231194265 [doi] LID - 09636897231194265 AB - While chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic gammadelta T-cell lymphoma refractory to multiple lines of chemotherapy, who eventually achieved first complete remission with flow cytometry-confirmed minimal residual disease negativity after human leukocyte antigen (HLA) fully-mismatched sibling-derived CD7 CAR-T therapy. However, given the allogeneic nature, CAR-T cells dropped rapidly after a peak of 83.4% of circulating T-cells. Cytokine release syndrome, cytopenia, and infections occurred but were manageable after treatments. After the consolidative haploidentical hematopoietic stem cell transplantation (HSCT), the patient remained in remission at the end of the follow-up (13 months post-CAR-T infusion). This is the first case of relapsed/refractory hepatosplenic gammadelta T-cell lymphoma who achieved lasting CR after HLA fully-mismatched sibling-derived CD7 CAR-T therapy bridging to haploidentical HSCT. FAU - Xu, Xueer AU - Xu X AUID- ORCID: 0009-0004-7707-8954 AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Zu, Cheng AU - Zu C AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Zhang, Mingming AU - Zhang M AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Xiao, Pingnan AU - Xiao P AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Hong, Ruimin AU - Hong R AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Feng, Jingjing AU - Feng J AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Xu, Huijun AU - Xu H AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Cui, Jiazhen AU - Cui J AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Yu, Jian AU - Yu J AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Shi, Jimin AU - Shi J AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Wei, Guoqing AU - Wei G AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Chang, Alex H AU - Chang AH AD - Shanghai YaKe Biotechnology Ltd., Shanghai, China. AD - Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Huang, He AU - Huang H AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. FAU - Hu, Yongxian AU - Hu Y AUID- ORCID: 0000-0001-9564-1852 AD - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. AD - Institute of Hematology, Zhejiang University, Hangzhou, China. AD - Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. LA - eng SI - ClinicalTrials.gov/NCT04599556 PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Cell Transplant JT - Cell transplantation JID - 9208854 RN - 0 (Receptors, Chimeric Antigen) RN - 0 (HLA Antigens) SB - IM MH - Humans MH - *Receptors, Chimeric Antigen MH - Siblings MH - *Hematopoietic Stem Cell Transplantation MH - Immunotherapy, Adoptive MH - HLA Antigens MH - *Lymphoma, T-Cell PMC - PMC10481705 OTO - NOTNLM OT - T-lymphocytes OT - immunology COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/09/05 06:42 MHDA- 2023/09/05 06:43 PMCR- 2023/09/04 CRDT- 2023/09/05 02:17 PHST- 2023/09/05 06:43 [medline] PHST- 2023/09/05 06:42 [pubmed] PHST- 2023/09/05 02:17 [entrez] PHST- 2023/09/04 00:00 [pmc-release] AID - 10.1177_09636897231194265 [pii] AID - 10.1177/09636897231194265 [doi] PST - ppublish SO - Cell Transplant. 2023 Jan-Dec;32:9636897231194265. doi: 10.1177/09636897231194265.